"The
Report Dry Eye Syndrome - US Drug Forecast and Market Analysis to
2024 provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
Dry
Eye Syndrome (DES),
also known as keratoconjunctivitis sicca, is a multifactorial disease
of the tears and ocular surface. This ocular condition can cause
ocular discomfort, visual disturbances, and tear film instability,
which can potentially damage the ocular surface. The DES market has
had few new therapeutics in the last decade with Japan seeing the
most change in this time with the arrival of Diquas and Mucosta in
2010 and 2013, respectively. However, the lack of treatment options
is about to change with the expected launch of numerous pipeline DES
drugs during the forecast period, which will be a significant driver
of growth in the 9MM. Indeed, this change has already been initiated
with Ikervis recent arrival in Europe in 2015. Furthermore,
additional marketing approvals are being sought for currently
marketed DES drugs, Restasis and Diquas, in new countries in the 9MM,
which will provide a source of growth in this market.
GlobalData estimates that DES
drug sales in the US reached $1.3 billion during 2014, making it the
largest market within the 9MM. After an initial period of minimal
growth, GlobalData estimates that the DES market will undergo a
period of steady growth from 2016 and beyond, but this growth will
begin to wane slightly towards the end of the forecast period. This
growth is mainly attributed to the expected introduction of the
highly anticipated pipeline DES drug, lifitegrast in late 2016, and
additional pipeline products in 2018. This expansion of treatment
options for DES patients will have the added effect of increasing
overall treatment rates in the US.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/785529
Scope
-
Overview of DES including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
-
Detailed information on the key drugs in the US including product
description, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in the US from 2014-2024.
-
Analysis of the impact of key events as well the drivers and
restraints affecting the US DES market.
Reasons to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for DES.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2014-2024 in US.
Table
of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 9
2.1 Related Reports 9
3 Disease Overview 11
3.1 Etiology and
Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 14
3.2 Disease Classification 16
3.3 Symptoms 17
3.4 Prognosis 20
3.5 Quality of Life 21
4 Disease Management 22
4.1 Diagnosis and Treatment
Overview 22
4.1.1 Diagnosis 22
4.1.2 Treatment Guidelines 25
4.1.3 Clinical Practice 26
4.2 US 32
5 Competitive Assessment 37
5.1 Overview 37
5.2 Product Profiles 38
5.2.1 Restasis (cyclosporine)
38
5.2.2 Diquas (diquafosol
tetrasodium) 48
5.2.3 Mucosta ophthalmic
solution (rebamipide) 54
5.2.4 Ikervis (cyclosporine) 59
5.2.5 Artificial Tears 66
5.2.6 Other therapies 74
6 Unmet Need and Opportunity 79
6.1 Overview 79
6.2 New Therapies for DES 81
6.2.1 Unmet Need 81
6.2.2 Gap Analysis 82
6.2.3 Opportunity 84
6.3 Better Diagnostic Tools 85
6.3.1 Unmet Need 85
6.3.2 Gap Analysis 86
6.3.3 Opportunity 88
6.4 Appropriate Clinical Trial
Design to Secure Regulatory Approval 89
6.4.1 Unmet Need 89
6.4.2 Gap Analysis 91
6.4.3 Opportunity 92
6.5 Simplified Dosing 93
6.5.1 Unmet Need 93
6.5.2 Gap Analysis 94
6.5.3 Opportunity 95
6.6 Patient Education to
Improve Tolerance and Compliance 95
6.6.1 Unmet Need 95
6.6.2 Gap Analysis 97
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment